Claudio Arrigoni

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Patrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini et al. · Molecular Cancer Therapeutics · 2007 · 240 citations

Histone H3, Potent Inhibitor, Cancer Biology +16

Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors

Shem Patyna, Claudio Arrigoni, Andrea Terron et al. · Toxicologic Pathology · 2008 · 89 citations

Chemoprevention Strategy, Potent Inhibitor, Pathology +16

Phenylimidazolidin-2-one Derivatives as Selective 5-HT₃Receptor Antagonists and Refinement of the Pharmacophore Model for 5-HT₃Receptor Binding

Franco Heidempergher, Antonio Pillan, Vittorio Pinciroli et al. · Journal of Medicinal Chemistry · 1997 · 34 citations · Full text

Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.

Cristina Geroni, Marina Ripamonti, Claudio Arrigoni et al. · PubMed · 2001 · 19 citations

Pharmaceutical Science, Toxicological Aspects, Pathology +20

PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential

Paola Della Torre, Arturo Podestà, A. R. Imondi et al. · Cancer Chemotherapy and Pharmacology · 2001 · 11 citations

Medicine, Low Cardiotoxic Potential, Pharmacotherapy +5